肺动脉高血压市场规模、份额和成长分析：按药物类别、类型、给药途径、分销管道和地区分类 - 2025-2032 年行业预测

2023年全球肺动脉高血压市场规模将为77.9亿美元，从2024年的82亿美元增长到2032年的124亿美元，预计在预测期内（2025-2032年）复合年增长率为5.3%。

由于几个关键因素，包括盛行率的增加、政府对孤儿药开发的支持增加以及老年人口的增加，肺动脉高血压（PAH）市场预计将成长。根据系统性评价，PAH的盛行率为每10万人0.4%至1.4%，全球30岁至79岁的人口估计有12.8亿人患有高血压，主要是低血压患者－受影响于中等收入国家。世界卫生组织设定了一个重要目标，从2010年到2030年将高血压盛行率降低33%，强调需要在这一领域进行进一步的研究和治疗方法。总而言之，这些发现为 PAH 治疗的进步带来了希望。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

肺动脉高血压市场规模：依药物类别

• 市场概况
• 内皮素受体拮抗剂（ERA）
• PDE-5抑制剂
• 前列腺环素和前列腺环素类似物
• SGC刺激器

肺动脉高血压市场规模：依类型

• 市场概况
• 品牌
• 非专利的

肺动脉高血压市场规模：依给药途径分类

• 市场概况
• 口服
• 静脉/皮下
• 吸入

肺动脉高血压市场规模：依通路分类

• 市场概况
• 医院
• 零售药房
• 网路药房

肺动脉高血压市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• United Therapeutics Corporation（United States）
• Bayer AG（Germany）
• GlaxoSmithKline plc（United Kingdom）
• Gilead Sciences, Inc.（United States）
• Novartis International AG（Switzerland）
• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• Bristol-Myers Squibb Company（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Viatris Inc.（United States）
• Sun Pharmaceutical Industries Ltd.（India）
• Alembic Pharmaceuticals Ltd.（India）
• Aerami Therapeutics Holdings Inc.（United States）
• Asklepion Pharmaceuticals LLC（United States）
• Keros Therapeutics（United States）
• Liquidia Corporation（United States）
• Ferrer（Spain）
• Gossamer Bio（United States）

结论和建议

Global Pulmonary Arterial Hypertension Market size was valued at USD 7.79 billion in 2023 and is poised to grow from USD 8.2 billion in 2024 to USD 12.4 billion by 2032, growing at a CAGR of 5.3% during the forecast period (2025-2032).

The pulmonary arterial hypertension (PAH) market is poised for growth due to several key factors, including the increasing incidence of the disease, enhanced government support for orphan drug development, and a growing elderly population. A systematic review highlighted the prevalence of PAH, indicating it affects between 0.4% and 1.4% of individuals per 100,000, with an estimated 1.28 billion people aged 30-79 globally affected by hypertension, predominantly in low- and middle-income countries. The WHO has set significant targets to reduce hypertension prevalence by 33% from 2010 to 2030, emphasizing the need for further research and treatment options in this area. Collectively, these insights set a promising stage for advancements in the PAH treatment landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pulmonary Arterial Hypertension market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pulmonary Arterial Hypertension Market Segmental Analysis

Global Pulmonary Arterial Hypertension Market is segmented by Drug Class, Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs and SGC Stimulators. Based on Type, the market is segmented into Branded and Generics. Based on Route of Administration, the market is segmented into Oral, Intravenous/ subcutaneous and Inhalational. Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pulmonary Arterial Hypertension Market

The global pulmonary arterial hypertension (PAH) market is experiencing significant growth due to the increasing prevalence of this rare yet progressive condition, which is characterized by elevated blood pressure in the arteries leading to the lungs. Factors contributing to this rise include aging populations, a growing incidence of risk factors such as obesity, and advancements in diagnostic techniques. Consequently, there is a heightened demand for effective PAH treatments. Furthermore, the development of innovative therapies, including prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, has bolstered market growth due to their improved efficacy and safety profiles, ultimately driving greater patient interest and need for these medications.

Restraints in the Global Pulmonary Arterial Hypertension Market

The global market for pulmonary arterial hypertension (PAH) faces certain constraints due to the limited pool of patients affected by this rare disease. Unlike more prevalent chronic conditions, PAH has a low incidence rate, which can significantly impact the commercial potential of therapeutic drugs designed for treatment and may deter investment in research and development. Additionally, diagnosing PAH requires a series of complex tests, including echocardiography, right heart catheterization, and pulmonary function assessments. Furthermore, symptoms such as fatigue and shortness of breath are often vague and can be misattributed to other health issues, resulting in delayed or incorrect diagnoses that hinder patient access to appropriate care.

Market Trends of the Global Pulmonary Arterial Hypertension Market

The Global Pulmonary Arterial Hypertension (PAH) market is witnessing a significant shift towards personalized medicine, driven by technological advancements and a deeper comprehension of the disease's genetic underpinnings. Pharmaceutical companies are heavily investing in research and development initiatives aimed at discovering biomarkers that can enhance the predictability of disease progression and treatment efficacy. This trend is fostering the creation of tailored therapies that specifically address varying genetic mutations associated with PAH, thereby improving patient outcomes. As a result, the market is poised for robust growth, characterized by innovation, a focus on individualized treatment regimens, and a commitment to precision healthcare solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Pulmonary Arterial Hypertension Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Endothelin Receptor Antagonists (ERAs)
• PDE-5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators

Global Pulmonary Arterial Hypertension Market Size by Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generics

Global Pulmonary Arterial Hypertension Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous/ subcutaneous
• Inhalational

Global Pulmonary Arterial Hypertension Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospitals
• Retail Pharmacies
• Online Pharmacies

Global Pulmonary Arterial Hypertension Market Size & CAGR (2025-2032)

• North America (Drug Class, Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• United Therapeutics Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alembic Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerami Therapeutics Holdings Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asklepion Pharmaceuticals LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Keros Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Liquidia Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferrer (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gossamer Bio (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations